On September 5th, hybio pharmaceutical (300199) announced the clinical progress of Semaglutide injection during an institutional investigation: the clinical study plan for Semaglutide injection for weight loss was first disclosed on September 2, 2024, on the 'Drug Clinical Trial Registration and Information Disclosure Platform', with registration number CTR20243301. It is the first domestic Semaglutide injection to enter Phase III clinical trials for weight management indications. The main purpose of the study is to evaluate the efficacy of hybio pharmaceutical's Semaglutide injection (HY310 injection) in assisting lifestyle intervention therapy for obese patients, using the original branded Semaglutide injection (NovoMix) as a control. The target enrollment is 408 participants.
翰宇药业：司美格鲁肽注射液减重三期临床研究方案近日公示
Hybio Pharmaceutical: the weight-reducing phase III clinical research plan of Semaglutide Injection was recently announced.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated